|Preferred IUPAC name
3D model (JSmol)
|Molar mass||576.72 g/mol|
|Appearance||Oleandrin forms colourless, odourless, acicular crystals that are very bitter|
|Melting point||250.0 °C (482.0 °F; 523.1 K)|
|Main hazards||Acute Toxicity (Oral, inhalation)|
|Safety data sheet||Safety Data Sheet|
|GHS Signal word||Danger|
|H300, H330, H373|
|P260, P264, P270, P271, P284, P301+310, P304+340, P310, P320, P330, P403+233, P405, P501|
|NFPA 704 (fire diamond)|
|Lethal dose or concentration (LD, LC):|
LD50 (median dose)
|0.248 mg/kg (Cat, Intravenous)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Oleandrin is a toxic cardiac glycoside found in the poisonous plant, oleander (Nerium oleander L.). As a main phytochemical of oleander, oleandrin is associated with the toxicity of oleander sap, and has similar properties to digoxin.
Oleander has been used in traditional medicine for its presumed therapeutic purposes, such as for treating cardiac insufficiency. There is no clinical evidence that oleander or its constituents, including oleandrin, are safe or effective. Oleandrin is not approved by regulatory agencies as a prescription drug or dietary supplement.
Structure and reactivity
The structure of oleandrin contains a central steroid nucleus with an unsaturated lactone ring structure on C17 and a dideoxy arabinose group on C3. In addition, the steroid ring has a substitute of an acetyloxy group on C16.
Oleandrin and its derivate oleandrigenin are formed in the N. oleander plant. The oleandrin itself can be won out of the leaves and other parts of the plant but can also be produced in the lab by using cell cultures. Here, the oleandrin synthesis (along with other metabolites) can be stimulated in untransformed plant cell cultures with supplementation of phytohormone. However, this is not enough to produce large quantities because of early cell death. Transgenic cultures of Agrobacteria are able to synthesize great quantities of oleandrin and other metabolites of the oleander plants, fit for pharmaceutical purposes.
Oleandrin is, apart from its pure form, also closely related to structural similar glycosides and alkaloids, which all have more or less the same characteristics as oleandrin:
- Oleandrigenin is a deglycosylated metabolite of oleandrin. It has however a more mild effect.
Although oleandrigenin is not formed in human plasma, it was found in the volunteers injected with oleandrin, suggesting that it is formed in other human tissues. Because of its lipophilic properties, oleandrin can be easily absorbed in the gastrointestinal tract after oral dosing. The clearance is slow. The plasma concentration obtains its maximum at twenty minutes after oral intake (half-life of about 2 hours, but half-life after IV administration is half an hour).
It is excreted mostly in feces, but also in urine. Because the main route of excretion is through biliary excretion into the feces, it is mainly the liver that is exposed to oleandrin. As excretion in urine is only a smaller route, the kidneys are less exposed. There is also accumulation in the heart, which explains its potential for cardiac toxicity.
Mechanism of action
Because of its properties as a cardiac glycoside, oleandrin interferes in some essential processes within the cell, the most important of these being the inhibition of the Na-K ATPase. This protein enables the cell to exchange the cations Na+ and K+ between the intercellular and extracellular spaces by which, for instance, electric signaling is made possible in nerve cells. Oleandrin binds to specific amino acids in the protein, causing it to lose its function. After depolarization of the cell in which Na+ flows into the cell, the Na+ cannot be transported back into the extracellular membrane, causing the sodium gradient to disappear. This gradient is the driving force for other transport proteins, such as the sodium-calcium exchanger, which plays an important role in cardiomyocytes.
To make muscle contraction possible, a calcium influx from the extracellular fluid into the cell is crucial. After the muscle contraction, the calcium is normally pumped out of the cell and exchanged for sodium. When the sodium gradient is depleted, calcium cannot be pumped back and, as a consequence, accumulates in the cardiomyocyte.
As a result of the high calcium concentration, actin and myosin filaments will bind stronger, unable to relax properly to make a new contraction possible. This may result in cardiac arrhythmias, in the worst case decreasing cardiac output and causing a shortage in oxygen supply in vital tissues.
Apart from being a potent toxic compound, it may also be used in therapeutic ways. Both oleandrin and oleandrigenin, as well as their relatives, may be able to inhibit proliferation of tumor cells and stimulate their apoptosis as a result of the high concentration of intracellular calcium. In addition, it inhibits excretion of fibroblast growth factor 2 through membrane interaction and through inhibition of the Na,K-ATPase pump. However, there are no results from clinical testing on humans that support any use as a cancer treatment.
Oleandrin has been reported to be lethal. In one fatality, the blood concentration of oleandrin and a related cardiac glycoside from the oleander plant was estimated at 20 ng/ml. In practice, there have been adult cases wherein 14–20 oleander leaves (of unknown oleandrin concentration) proved not to be fatal, but also a lethal case of a child that consumed only one leaf.
Symptoms of oleandrin poisoning can cause both gastrointestinal and cardiac effects. The gastrointestinal effects can consist of nausea, abdominal pain, and vomiting, as well as higher salivation and diarrhea (which may contain blood). After these first symptoms, the heart may be affected by tachyarrhythmia, bradyarrhythmia, premature ventricular contractions, or atrioventricular blockage. Also, xanthopsia (yellow vision), a burning sensation of the mucous membranes of the eyes, and gastrointestinal tract and respiratory paralysis can occur. Reactions to poisonings from this plant can also affect the central nervous system. These symptoms can include drowsiness, tremors, or shaking of the muscles, seizures, collapse, and even coma that can lead to death. Oleander sap can cause skin irritations, severe eye inflammation and irritation, and allergy reactions characterized by dermatitis when administered topically.
Diagnosis of oleandrin poisoning is mainly based on description of the plant, how much of it was ingested, time since ingestion, and symptoms.
Three methods are used for detecting oleandrin in the blood. Fluorescence polarization immunoassay is widely used. This test is slower and has a lower sensitivity than digoxin immunoassay (Digoxin III). A direct analytic technique like liquid chromatography-electrospray tandem mass spectrometry is used when there are medicolegal issues.
Oleander toxicity should be treated aggressively, including as needed gastric lavage or induced emesis. Onset of symptoms may vary with the way of intake. Teas made of leaves or root of N. oleander give rise to a more acute onset, while eating raw leaves causes a slower onset of symptoms. Management of oleandrin poisoning is done in the following steps:
There is a lack of evidence that weighs efficacy versus harm. Activated charcoal is still used, since it binds toxins in the gastrointestinal tract to reduce absorption. It is uncertain whether repeated administration of activated charcoal is effective, in theory interrupting enterohepatic cycling. This treatment is used for digoxin poisoning, another cardiac glycoside. Supportive care like monitoring vitals and electrolyte and fluid balance is important. Patients may present hypovolemic due to vomiting and diarrhea, but severely elevated potassium can also occur. Electrolyte balance is vital, since patients with low cardiac glycoside levels can still die after adequate digoxin Fab antibody treatment if they have disturbed electrolyte levels.
Treatment of slow heart rate and heart rhythm irregularities may require intravenous isoprenaline or atropine. In moderate cases, prolonging of the PR interval and progression to AV dissociation, cardiac pacing is used.
The effectiveness of all these interventions is unknown and are associated with side-effects. Therefore, consultation with a cardiologist is recommended when managing significant N. Oleander induced arrhythmias. The use of anti-digoxin Fab IV has proven successful in cases of oleandrin poisoning
A dose of 400 mg is used in digoxin poisoning, but a dose of 800 mg is recommended for oleandrin poisoning due to the lower binding affinity of the antibody to oleandrin. Patients receiving an adequate dose of anti-digoxin Fab show a good response, resolving serious arrhythmias in two hours in fifty percent of the cases. Treated patients showed a rapid increase in heart rate and a significant decline in serum potassium levels. The reason anti-digoxin Fab is sparingly used in developing countries is its high cost, even though it is such an effective treatment.
Although oleander has been used in traditional medicine for treating various disorders, there is no evidence that it is safe or effective for any medicinal purpose. Due to its considerable toxicity, use of oleander or its constituents, such as oleandrin, is regarded as unsafe and potentially lethal. Use of oleander may cause contact dermatitis, headache, nausea, lethargy, and high blood levels of potassium, with symptoms appearing within a few hours of ingestion.
As a dietary supplement
During the COVID-19 pandemic, Donald Trump's Secretary of Housing and Urban Development Ben Carson, and MyPillow CEO Mike Lindell, a major Trump booster and an investor in a company that develops oleandrin, promoted oleandrin as a potential treatment of the disease in a July 2020 Oval Office meeting with Trump, who expressed enthusiasm for the substance. These claims were widely regarded by scientists as dubious, misleading, and alarming, as well as having no clinical proof of safety or effectiveness.
The unproven claims of benefit further caused concern among scientists that the Trump administration may force unwarranted FDA approval of oleandrin as a safe and effective treatment for COVID-19 infection. However, on 14 August 2020, the FDA rejected the application for marketing an oleandrin dietary supplement by Phoenix Biotechnology, Inc. – the manufacturer of the product – due to concerns that oleandrin would not be safe to consume.
Effects on animals
Oleandrin poisoning by eating oleander leaves can be lethal at low dosages. Cases of sheep lethality have been reported to only one leaf of oleander. Symptoms present in poisoned animals include bloody diarrhea and colic, the latter especially in horses. Because the leaf itself is quite bitter, only starving animals will be likely to eat the plant. The lethal dosage for animals is estimated to be about 0.5 mg/kg.
- "Oleander". Drugs.com. 1 December 2018. Retrieved 17 August 2020.
- Jortani, Saeed A.; Helm, R. Allen; Valdes, Roland (1996). "Inhibition of Na,K-ATPase by oleandrin and oleandrigenin, and their detection by digoxin immunoassays". Clinical Chemistry. 42 (10): 1654–8. doi:10.1093/clinchem/42.10.1654. PMID 8855150.[permanent dead link]
- Ibrahim, Amany K.; Khalifa, Sherief; Youssef, Diaa; Khan, Ikhlas; Mesbah, I; Mesbah, M (2007). "Stimulation of oleandrin production by combined Agrobacterium tumefaciens mediated transformation and fungal elecitation in Nerium oleander cell cultures". Enzyme and Microbial Technology. 41 (3): 331–66. doi:10.1016/j.enzmictec.2007.02.015.
- Wang, Xiaomin; Plomley, Jeffry B.; Newman, Robert A.; Cisneros, Angela (2000). "LC/MS/MS Analyses of an Oleander Extract for Cancer Treatment". Analytical Chemistry. 72 (15): 3547–52. doi:10.1021/ac991425a. PMID 10952541.
- Ni, Dan; Madden, Timothy L.; Johansen, Mary; Felix, Edward; Ho, Dah H.; Newman, Robert A. (2002). "Murine pharmacokinetics and metabolism of oleandrin, a cytotoxic component of Nerium oleander". Journal of Experimental Therapeutics and Oncology. 2 (5): 278–85. doi:10.1046/j.1359-4117.2002.01052.x. PMID 12416031.
- Timbrell, J. A. (2009). Principles of Biochemical Toxicology. New York: Informa Healthcare. pp. 349–51. ISBN 978-0-8493-7302-2.
- Yang, P.; Menter, D. G.; Cartwright, C.; Chan, D.; Dixon, S.; Suraokar, M.; Mendoza, G.; Llansa, N.; Newman, R. A. (2009). "Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase subunits as drug targets". Molecular Cancer Therapeutics. 8 (8): 2319–2328. doi:10.1158/1535-7163.MCT-08-1085. PMID 19671733.
- "More information on complementary and alternative medicine | American Cancer Society".
- Wasfi, I; Zorob, O; Alkatheeri, N; Alawadhi, A (2008). "A fatal case of oleandrin poisoning". Forensic Science International. 179 (2–3): e31–6. doi:10.1016/j.forsciint.2008.05.002. PMID 18602779.
- "Nerium oleander L.(PIM 366)". IPCS Inchem. 2005. Retrieved 2005-10-23.
- Goetz, Rebecca. J.; Jordan Thomas N.; McCain, John W.; Su, Nancy Y. (1998). "Oleander". Indiana Plants Poisonous to Livestock and Pets. Cooperative Extension Service, Purdue University. Archived from the original on 2005-10-21. Retrieved 2005-10-23.
- Actor, Jeffrey K.; Reyes, Meredith; Risin, Semyon A.; Dasgupta, Amitava (2008). "Rapid Detection of Oleander Poisoning by Digoxin III, a New Digoxin Assay: Impact on Serum Digoxin Measurement". American Journal of Clinical Pathology. 129 (4): 548–553. doi:10.1309/CC6791DFF20QPCX3. PMID 18343781.
- Tor, Elizabeth R.; Filigenzi, Michael S.; Puschner, Birgit (2005). "Determination of Oleandrin in Tissues and Biological Fluids by Liquid Chromatography−Electrospray Tandem Mass Spectrometry". Journal of Agricultural and Food Chemistry. 53 (11): 4322–5. doi:10.1021/jf050201s. PMID 15913289.
- Haynes, B; Bessen, H; Wightman, W (1985). "Oleander tea: Herbal draught of death". Annals of Emergency Medicine. 14 (4): 350–3. doi:10.1016/S0196-0644(85)80103-7. PMID 4039113.
- Bandara, V; Weinstein, SA; White, J; Eddleston, M (2010). "A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning". Toxicon. 56 (3): 273–81. doi:10.1016/j.toxicon.2010.03.026. PMID 20438743.
- Eddleston, Michael; Haggalla, Sapumal; Reginald, K.; Sudarshan, K.; Senthilkumaran, M.; Karalliedde, Lakshman; Ariaratnam, Ariaranee; Sheriff, M.H.Rezvi; et al. (2007). "The hazards of gastric lavage for intentional self-poisoning in a resource poor location". Clinical Toxicology. 45 (2): 136–43. doi:10.1080/15563650601006009. PMC 1941903. PMID 17364630.
- Reissell, P; Manninen, V (1982). "Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides". Acta Medica Scandinavica. Supplementum. 668: 88–90. doi:10.1111/j.0954-6820.1982.tb08527.x. PMID 6963097.
- Rajapakse, Senaka (2009). "Management of yellow oleander poisoning". Clinical Toxicology. 47 (3): 206–12. doi:10.1080/15563650902824001. PMID 19306191. S2CID 37334350.
- Eddleston, M.; Warrell, DA (1999). "Management of acute yellow oleander poisoning". QJM. 92 (9): 483–5. doi:10.1093/qjmed/92.9.483. PMID 10627866.
- Peiris-John, RJ; Wickremasinghe, AR (2008). "Efficacy of activated charcoal in yellow oleander poisoning". The Ceylon Medical Journal. 53 (2): 33–5. doi:10.4038/cmj.v53i2.228. PMID 18678118.
- Eddleston, M.; Ariaratnam, C. A.; Meyer, W. P.; Perera, G.; Kularatne, A. M.; Attapattu, S.; Sheriff, M. H. R.; Warrell, D. A. (1999). "Epidemic of self-poisoning with seeds of the yellow oleander tree (Thevetia peruviana) in northern Sri Lanka". Tropical Medicine and International Health. 4 (4): 266–73. doi:10.1046/j.1365-3156.1999.00397.x. PMID 10357862.
- Camphausen, C.; Haas, N. A.; Mattke, A. C. (2005). "Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child". Zeitschrift für Kardiologie. 94 (12): 817–23. doi:10.1007/s00392-005-0293-3. PMID 16382383. S2CID 25517175.
- Bandara, Veronika; Weinstein, Scott A.; White, Julian; Eddleston, Michael (2010). "A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and Thevetia peruviana (yellow oleander) poisoning". Toxicon. 56 (3): 273–81. doi:10.1016/j.toxicon.2010.03.026. PMID 20438743.
- Eddleston, M; Rajapakse, S; Rajakanthan; Jayalath, S; Sjöström, L; Santharaj, W; Thenabadu, PN; Sheriff, MHR; Warrell, DA (2000). "Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial". The Lancet. 355 (9208): 967–72. doi:10.1016/S0140-6736(00)90014-X. PMID 10768435. S2CID 2095538.
- Eddleston, Michael; Senarathna, Lalith; Mohamed, Fahim; Buckley, Nick; Juszczak, Edmund; Sheriff, MH Rezvi; Ariaratnam, Ariaranee; Rajapakse, Senaka; et al. (2003). "Deaths due to absence of an affordable antitoxin for plant poisoning". The Lancet. 362 (9389): 1041–4. doi:10.1016/S0140-6736(03)14415-7. PMID 14522536. S2CID 20194201.
- Jonathan Swan (2020-08-17). "Trump eyes new unproven coronavirus "cure"". Axios. Retrieved 2020-08-17.
- Lauren Frias (2020-08-17). "Trump reportedly pushing new unproven coronavirus treatment that is also embraced by HUD Sec. Ben Carson and MyPillow's Mike Lindell". Business Insider. Retrieved 2020-08-17.
- Philip Rucker, Yasmeen Abutaleb, Josh Dawsey and Robert Costa (August 8, 2020). "The lost days of summer: How Trump fell short in containing the virus". Washington Post.
The president recently hosted Andrew Whitney, a biopharmaceuticals executive on the board of a company called Phoenix, who met in the Oval Office with Trump. Whitney, who has a limited health background, pitched Trump on a botanical extract called oleandrin as a treatment for the coronavirus, according to two senior administration officials with knowledge of the discussion. One official said Mike Lindell, a Trump booster and the chief executive of MyPillow — who stars as pitchman for his product in advertising on some of the Fox News shows Trump watches — helped arrange the meeting. Since then, Whitney has personally made overtures to senior leaders at the Food and Drug Administration, including its commissioner, Stephen Hahn, in an effort to get the agency to approve oleandrin as a treatment for the coronavirus.CS1 maint: multiple names: authors list (link)
- Lev Facher (27 August 2020). "Trump has launched an all-out attack on the FDA. Will its scientific integrity survive?". STAT. Retrieved 29 August 2020.
- Novella, Steven. "Oleandra – The New COVID Snake Oil". Science Based Medicine. Retrieved 28 August 2020.
- Jen Christensen; Jamie Gumbrecht (4 September 2020). "FDA rejects oleandrin, an unproven coronavirus therapeutic pushed by MyPillow CEO, as a dietary supplement ingredient". CNN. Retrieved 4 September 2020.
- Soto-Blanco, B.; Fontenele-Neto, J. D.; Silva, D. M.; Reis, P. F.; Nóbrega, J. E. (2006). "Acute cattle intoxication from Nerium oleander pods". Tropical Animal Health and Production. 38 (6): 451–454. doi:10.1007/s11250-006-4400-x. PMID 17243471. S2CID 7361800.